GlaxoSmithKline News and Research

RSS

WHO using new bivalent oral polio vaccine in Afghanistan

The WHO on Tuesday launched a vaccination campaign in Afghanistan that will use "a new and more effective polio vaccine" for the first time, Reuters reports (Nebehay, 12/15).

16 Dec 2009

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

News outlets continued to follow UNITAID's recent announcement to create a patent pool aimed at lowering the cost of HIV/AIDS drugs for low- and middle-income countries. Though UNITAID's board "voted Monday to create a board to run the new patent pool, and set a target of having five AIDS drugs in the pool by mid-2010," the group "punted on the thorny issue of which countries outside of Africa to include in the pool," Forbes reports.

16 Dec 2009

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

16 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Avandia lawsuit: GSK's claims of privilege rejected

In a decision of importance to the case at hand and all cases involving claims of attorney-client or work product privilege, the Honorable Cynthia M. Rufe of the United States District Court for the Eastern District of Pennsylvania, in a decision of December 7, 2009, has ruled that GlaxoSmithKline (GSK), the manufacturer of the prescription diabetes medication Avandia, must produce dozens of documents that it withheld on claims of privilege.

11 Dec 2009

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

"Flu vaccine shortages in developing nations may destabilize global security should the H1N1 [swine flu] virus become more deadly … David Heymann, a former deputy head of the World Health Organization" said Monday, Bloomberg reports.

10 Dec 2009

Despite worldwide outbreak of H1N1 virus, American adults not eager to get vaccinated

American adults are not being vaccinated against the seasonal flu any more often than they were last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus, according to a new RAND Corporation study.

10 Dec 2009

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Seasonal flu vaccination rates among American adults have only slightly improved over last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus.

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA (www.anti-infectivesummit.com). This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

From IQPC Ltd 10 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

The West African Rotavirus Advisory Board is calling on governments to vaccinate children against rotavirus, IRIN reports. At a recent meeting in Dakar, Senegal, which was "financed by GlaxoSmithKline, makers of one of two rotavirus vaccines" the board issued a document recommending that governments "immediately recognize the magnitude of the rotavirus problem and make vaccination against the virus a priority" (12/8).

8 Dec 2009

Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug

Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK).

8 Dec 2009

Scientists report cervarix vaccine offers protection against cervical cancer

The Cervarix vaccine provides protection against two types of human papillomavirus (HPV) for more than six years, US scientists have reported.

5 Dec 2009

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

UK DFID awards CNTD £10M in elimination of elephantiasis initiative

The Centre for Neglected Tropical Diseases (CNTD) at the Liverpool School of Tropical Medicine has been awarded £10 million by the UK Department for International Development (DFID) to support endemic countries in tackling lymphatic filariasis (LF) - a crippling disease more commonly known as elephantiasis.

3 Dec 2009

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

The number of H1N1 (swine flu) cases in the U.S. appears to be decreasing, the CDC said Tuesday, CQ HealthBeat reports. "Flu was widespread in 32 states by the end of the week of Nov. 21, a decrease from 43 states in the prior week and 46 states earlier this fall, according to the CDC," the news service writes. "

3 Dec 2009

Several new vaccines require booster shots to remain effective during a lifetime: Study

Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong?

24 Nov 2009

Gilead Sciences and GSK to commercialize Viread in 5 Asian countries

Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies’ combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is greater than 8 percent.

24 Nov 2009

GlaxoSmithKline News and Research

WHO using new bivalent oral polio vaccine in Afghanistan

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

Combination therapy improves overall survival in women with advanced breast cancer

Avandia lawsuit: GSK's claims of privilege rejected

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

Despite worldwide outbreak of H1N1 virus, American adults not eager to get vaccinated

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug

Scientists report cervarix vaccine offers protection against cervical cancer

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

UK DFID awards CNTD £10M in elimination of elephantiasis initiative

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

Several new vaccines require booster shots to remain effective during a lifetime: Study

Gilead Sciences and GSK to commercialize Viread in 5 Asian countries

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News